# WEEKLY EPIDEMIOLOGY BULLETIN NATIONAL SURVEILLANCE UNIT, MINISTRY OF HEALTH & WELLNESS, JAMAICA

Weekly Spotlight

# **Poliomyelitis (Part 1)**



# Overview

In 1988, the World Health Assembly adopted a resolution for the worldwide eradication of polio, marking the launch of the Global Polio Eradication Initiative

(GPEI), a unique global public-private partnership. Since then, the incidence of polio worldwide has been reduced by 99%, and the world stands on the threshold of eradicating a human disease globally for only the second time in history, after smallpox in 1980.

Wild poliovirus cases have decreased by over 99% since 1988, from an estimated 350 000 cases in more than 125 endemic countries then, to two endemic countries).

# Symptoms and risk

Polio is a highly infectious disease caused by a virus. It invades the nervous system and can cause total paralysis in a matter of hours. The virus is transmitted by person-to-person spread mainly through the faecal-oral route or, less frequently, by a common vehicle (for example, contaminated water or food) and multiplies in the intestine. Initial symptoms are fever, fatigue, headache, vomiting, stiffness of the neck and pain in the limbs. One in 200 infections leads to irreversible paralysis (usually in the legs). Among those paralysed, 5–10% die when their breathing muscles become immobilized.

Polio mainly affects children under 5 years of age. However, anyone of any age who is unvaccinated can contract the disease.

There is no cure for polio, it can only be prevented. Polio vaccine, given multiple times, can protect a child for life. There are two vaccines available: oral polio vaccine and inactivated polio vaccine. Both are effective and safe, and both are used in different combinations worldwide, depending on local epidemiological and programmatic circumstances, to ensure the best possible protection to populations can be provided.

Taken from WHO website on 9/April/2025 https://www.who.int/news-room/fact-sheets/detail/poliomyelitis Pictures taken from https://health.thefuntimesguide.com/getting-tetanus-shot/



#### SENTINEL SYNDROMIC SURVEILLANCE

# Sentinel Surveillance in Jamaica



Table showcasing the Timeliness of Weekly Sentinel Surveillance Parish Reports for the Four Most Recent Epidemiological Weeks – 9 to 12 of 2025

Parish health departments submit reports weekly by 3 p.m. on Tuesdays. Reports submitted after 3 p.m. are considered late.

#### KEY:

Yellow- late submission on Tuesday Red – late submission after Tuesday A syndromic surveillance system is good for early detection of and response to public health events.

ISSN 0799-3927

Sentinel surveillance occurs when selected health facilities (sentinel sites) form a network that reports on certain health conditions on a regular basis, for example, weekly. Reporting is mandatory whether or not there are cases to report.

Jamaica's sentinel surveillance system concentrates on visits to sentinel sites for health events and syndromes of national importance which are reported weekly (see pages 2 -4). There are seventy-eight (78) reporting sentinel sites (hospitals and health centres) across Jamaica.



# REPORTS FOR SYNDROMIC SURVEILLANCE

## UNDIFFERENTIATED FEVER

Temperature of  $>38^{\circ}C$ /100.4°*F* (or recent history of fever) with or without an obvious diagnosis or focus of infection.





Weekly Visits to Sentinel Sites for Undifferentiated Fever All ages: Jamaica,

2 NOTIFICATIONS-All clinical sites

NS-

INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





#### April 11, 2025

# FEVER AND NEUROLOGICAL

Temperature of >38°C /100.4°F (or recent history of fever) in a previously healthy person with or without headache and vomiting. The person must also have meningeal irritation, convulsions, altered consciousness, altered sensory manifestations or paralysis (except AFP).



ISSN 0799-3927

Weekly visits to Sentinel Sites for Fever and Haemorrhagic 2024 and 2025 vs Weekly Threshold; Jamaica





- 3
  - NOTIFICATIONS-All clinical sites

**INVESTIGATION** REPORTS- Detailed Follow up for all Class One Events

HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



SENTINEL REPORT- 78 sites. Automatic reporting

**FEVER AND** 

/100.4<sup>o</sup>*F* (or recent history of fever) in a previously healthy person presenting with at least one haemorrhagic (bleeding) manifestation with or without jaundice.



## **FEVER AND JAUNDICE**

Temperature of  $>38^{\circ}C/100.4^{\circ}F$ (or recent history of fever) in a previously healthy person presenting with jaundice.

The epidemic threshold is used to confirm the emergence of an epidemic in order to implement control measures. It is calculated using the mean reported cases per week plus 2 standard deviations.



4 NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





#### ISSN 0799-3927

# CLASS ONE NOTIFIABLE EVENTS

# Comments

			Confirm	ned $\text{YTD}^{\alpha}$	AFP Field Guides from
	CLASS 1 E	VENTS	CURRENT YEAR 2025	PREVIOUS YEAR 2024	WHO indicate that for an effective surveillance system, detection rates for
	Accidental Po	oisoning	12 <sup>β</sup>	110 <sup>β</sup>	AFP should be 1/100,000
Ł	Cholera		0	0	population under 15 years
ON	Severe Deng	ue <sup>γ</sup>	See Dengue page below	See Dengue page below	
IATI	COVID-19 (\$	SARS-CoV-2)	49	160	Pertussis-like syndrome and
ERN	Hansen's Dis	ease (Leprosy)	0	0	Tetanus are clinically
TINT	Hepatitis B		0	11	
	Hepatitis C		1	4	Y Dengue Hemorrhagic
NOI	HIV/AIDS		NA	NA	Fever data include Dengue
TAT	Malaria (Imp	ported)	0	0	
4	Meningitis		4	8	$\delta$ Figures include all deaths
	Monkeypox		0	0	associated with pregnancy reported for the period
EXOTIC/ UNUSUAL	Plague		0	0	
XT XT	Meningococc	cal Meningitis	0	0	CHIKV IgM positive
GH IDI ALI	Neonatal Tet	anus	0	0	$\theta$ Zika PCR positive cases
H I DRB DRT	Typhoid Feve	er	0	0	$\beta$ Undates made to prior
ŇŇ	Meningitis H	/Flu	0	0	weeks.
	AFP/Polio		0	0	$^{\alpha}$ Figures are cumulative
	Congenital R	ubella Syndrome	0	0	totals for all epidemiologica
70	Congenital S	yphilis	0	0	weeks year to date.
MES	Fever and	Measles	0	0	4
RAM	Rash	Rubella	0	0	
(OC	Maternal Dea	ιths <sup>δ</sup>	18	14	
L PR	Ophthalmia N	Neonatorum	7	43	_
CIA	Pertussis-like	syndrome	0	0	
SPE	Rheumatic Fe	ever	0	0	_
	Tetanus		1	0	_
	Tuberculosis		0	17	
	Yellow Fever	ſ	0	0	
	Chikungunya	ε	0	0	
	Zika Virus <sup>6</sup>		0	0	NA- Not Available

NOTIFICATIONS-5 All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





April 11, 2025							1	SSI	0 /	799-	392	27													
		COVII	)-19	) Si	urv	vei]	lla	n	e	Up	da	te													
CASES	EW 13	Total				Clas	sifica	atio	n of Sy	Conf	irme oms,	d CO Jam	) DVII aica	D-19 n (1)	9 Ca 57,4	ises 184	s by ca	/ Da ses	ate )	of	On	set	: of	:	
Confirmed	4	157484	S	2000 1800 1600	) )																				
Females	1	90736	ned case	1400 1200 1000 800	) ) )			4																	
Males	3	66745	confirm	600 400 200	) ) )	ļ	llharmi						intellisis.												
Age Range	0 to 75 years	1 day to 108 years	No. of	C	1-Mar-20	1-Jul-20 1-Sep-20	1-Nov-20	1-Jan-21 1-Mar-21	1-May-21	1-Sep-21 1-Nov-21	1-Jan-22 1-Mar-22	1-May-22	1-Jul-22 1-Sep-22	1-Nov-22	1-Jan-23 1-Mar-23	1-May-23	1-Jul-23	1-Sep-23	1-Jan-24	1-Mar-24	1-May-24	1-Jul-24	1-Sep-24 1-Nov-24	1-Jan-25	1-Mar-25
* 3 positive cases ha * PCR or Antigen tes * Total represents a to the current Epi-	d no gender specific ts are used to confir Il cases confirmed fro Week.	ation m cases om 10 Mar 2020		Con	tact of a	a Confir missior	med C	Case Epi Li	nked)	Dat Im	e of port R ider In	Ons elated vestig	et of ation	fSyı	mpto	om	s	∎ Im ■ We	porte orkpl	ed ace (	Clus	ter			
COVID-19 Outc	omes																								
COVID-19 Outc Outcomes	omes EW 13	Total			3312	2 CO	VID-	-19	Rel	ated	Dea	ths	sin	ce	Ma	rch	n 1,	20	21	- `	ΥT	D			
COVID-19 Outcomes ACTIVE *2 weeks*	omes EW 13	Total			3312	2 CO Va	VID- ccin	-19 nati	Rel on S	ated Statu	Dea s an	ths non	sin g C(	ce DVI	Ma D-1	rch L9 I	n 1, Dea	20 ath	)21 s	- `	YT	D			
Outcomes ACTIVE *2 weeks* DIED – COVID Related	omes EW 13 0	Total     10     3876	F	- Fully V	3312 accina 3	2 CO Va ted (10	VID- ccin	-19 nati 11)	Rel on S	ated Statu	Dea s an	ths	sin g C(	ce   DVI	Ma D-1	rch L9 I	n 1, Dea	20 ath	)21 s	- `	Pa Vac (42/3	D artia ccina 3311	atec	1	
COVID-19 Outco Outcomes ACTIVE *2 weeks* DIED – COVID Related Died - NON COVID	omes EW 13 0 0	Total     10     3876     396	F	- Fully V	3312 accina 3	2 CO Va ted (10%	VID- ccin	-19 nati	Rel on S	ated Statu	Dea s am	ths non	sin g C(	ce   DVI	Ma D-1	rch L9 I	n 1, Dea	20 ath	)21  s	`	YT Pa Vac (42/	D artia ccina 3311	llly atec 1) 19	I %	
COVID-19 Outco Outcomes ACTIVE *2 weeks* DIED – COVID Related Died - NON COVID Died - Under Investigation	omes <b>EW 13</b> 0 0 0 0	Total     10     3876     396     142	F	<sup>-</sup> ully V	3312 accina 3	2 CO Va ted (10%	VID- ccin	-19 nati	Rel on S	ated Statu	Dea s an	ths	sin g CC	ce   DVI	Ma D-1	rch L9 I	n 1, Dea	20 ath	)21 s		Pi Vac (42/:	D artia ccina 3311	illy atec 1) 19	I %	
COVID-19 Outco Outcomes ACTIVE *2 weeks* DIED – COVID Related Died - NON COVID Died - Under Investigation Recovered and discharged	omes <b>EW 13</b> 0 0 0 0 0	Total     10     3876     396     142     103226	F	- ully V	3312 accina 3	2 CO Va	VID- ccin	-19 nati	Rel	ated Statu	Dea s an	ths	sin g CC	ce   DVI	Ma D-1	rch L9 I	n 1, Dea	, 20 ath	)21 s	`	Pa Vac (42/3	D artia ccina 3311	atec	i %	
COVID-19 Outco Outcomes ACTIVE *2 weeks* DIED – COVID Related Died - NON COVID Died - Under Investigation Recovered and discharged Repatriated	omes EW 13 0 0 0 0 0 0 0 0	Total     10     3876     396     142     103226     93	F	-Fully V	3312 accina 3	2 CO' Va tted (11	VID- ccin	-19 nati	Rel on S	ated Statu	Dea s am u (3	ths non	sin g CC	ce DVI	Ma D-1	rch L9 I	n 1, De	20 ath	)21 s	^	Pa Vac (42/	D artia ccina 3311	ally atec 1) 19	1 %	
COVID-19 Outcomes ACTIVE *2 weeks* DIED - COVID Related Died - NON COVID Died - Under Investigation Recovered and discharged Repatriated Total	omes EW 13 0 0 0 0 0 0 0	Total     10     3876     396     142     103226     93     157484	F	-ully V	3312 accina 3	2 CO Va	VID- ccin	-19 nati	Rel on S	ated Statu	Dea s am u	nvac 169/3	sin g CC	ce DVI	Ma D-1	rch L9 I	n 1, Dea	20 ath	)21  s	`	<b>YT</b> Vac (42/3	D artia ccina 3311	ally atec 1) 19	1 %	
COVID-19 Outcomes ACTIVE *2 weeks* DIED – COVID Related Died - NON COVID Died - Under Investigation Recovered and discharged Repatriated Total *Vaccination program * Total as at current	Omes EW 13 0 0 0 0 0 0 0 0 0 mme March 2021 – Y Epi week	Total   10   3876   396   142   103226   93   157484	F	Fully V	3312 accina 3	2 CO Va tted (11	viD- ccin	- <b>19</b> nati	Rel on S	ated Statu	Dea s am (3 rtial	nvac 169/3	sin g CC	tted 96%	Ma D-1	rch L9 I	n 1, De:	. 20 ath	Jnv	``	P: Vac (42/	D artia ccina 3311	ally atec 1) 19	i %	
COVID-19 Outco Outcomes ACTIVE *2 weeks* DIED - COVID Related Died - NON COVID Died - Under Investigation Recovered and discharged Repatriated Total *Vaccination program * Total as at current COVID-19 Pari	Omes EW 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total     10     3876     396     142     103226     93     157484     TD	F	Fully V	3312 accina 3	2 CO Va ted (11	VID- ccin p1/331	-19 nati	Rel on S	ated Statu	Dea s an u (3 rtial	nvac 169/3	sin g CC	tted 96%	Ma D-1	rch L9 I	n 1, Dea	. 20 ath	Jnv	` /ac	Pa Vac (42/	D artia 3311	ally atec 1) 19	i %	





6 NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





#### April 11, 2025

# NATIONAL SURVEILLANCE UNIT INFLUENZA REPORT

# EW 13

ISSN 0799-3927

### March 23, 2025 – March 29, 2025 Epidemiological Week 13



ISSN 0799-3927



2007 2008 2009

2004 2005 2006

Total Suspected, probable & confirmed Confirmed DF

2015 2016

Year

2018 2019

2017

2020 2021 2022 2023 2023 2024 2025

2010

2011 2012 2013 2014



Reported suspected, probable and

2025\*

0

0

EW 13

0

0

0

**Dengue deaths are reported** 

\*Figure as at, April 11, 2025

are reported as confirmed.

as presumed dengue.

**Only PCR positive dengue cases** 

IgM positive cases are classified

based on date of death.

week 13 of 2025

Total Suspected,

**Probable & Confirmed** 

**Dengue Cases** 

Lab Confirmed Dengue

cases

CONFIRMED

**Dengue Related Deaths** 

**Points to note:** 

Ō



Suspected, probable and confirmed dengue cases for 2023-2025 versus monthly mean, alert and epidemic threshold (2007-2022)



NOTIFICATIONS-8 All clinical sites



**INVESTIGATION REPORTS-** Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





# **RESEARCH PAPER**

## Abstract

# NHRC-23-010

## Fruit and vegetable intake among Jamaican school-aged children

Gray Brown A<sup>1</sup>, Findlay L<sup>1</sup>, Soares-Wynter S.<sup>1</sup>

<sup>1</sup>Caribbean Institute for Health Research, The University of the West Indies, Kingston, Jamaica.

**Objective:** To describe the weekday fruit and vegetable intakes of Jamaican school-aged children.

**Methods:** A cross-sectional survey of children (n=729), aged 7-11 years, from 30 primary schools in Kingston and St. Andrew was conducted in 2019. Fruit and vegetable intakes were reported using a modified 24-hour recall administered by trained nutrition personnel with the aid of food models. Intake estimates were converted to grams and compared to World Health Organization (WHO) requirements. Data were presented as means and frequencies where appropriate.

**Results:** Fruits and vegetables were consumed by 35% (262) and 52% (377) of children, respectively. Among the consumers, fruits eaten were obtained mostly from home (174, 66%), street vendors (50, 19%), school (45, 17%), or other locations (27, 10%). Vegetables were also obtained from home (229, 61%), school (197, 52%) or other locations (15, 4%). The most frequently reported items were ripe bananas, otaheite apples, and oranges; and cabbage, lettuce, and mixed vegetables (green peas, carrot, corn). Most fruits were consumed at breakfast meals (111, 42%) or as snacks throughout the day (117, 45%). In contrast, vegetables were consumed mostly for lunch (209, 55%) and dinner (203, 54%) meals. The mean amounts consumed were  $38.4\pm63.4g$  fruits and  $76.3\pm140.8g$  vegetables, and only 9% of children met their age-specific WHO fruit and vegetable requirement.

**Conclusion:** Many Jamaican school children report eating fruits and vegetables but intakes are inadequate. A comprehensive school nutrition policy provides a unique opportunity to incorporate fruits and vegetables in school meal programmes.



The Ministry of Health and Wellness 15 Knutsford Boulevard, Kingston 5, Jamaica Tele: (876) 633-7924 Email: surveillance@moh.gov.jm



q

NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued

